Edition:
United Kingdom

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

14.57USD
21 Sep 2018
Change (% chg)

$0.54 (+3.85%)
Prev Close
$14.03
Open
$14.20
Day's High
$14.95
Day's Low
$13.90
Volume
1,296,991
Avg. Vol
185,210
52-wk High
$14.95
52-wk Low
$3.55

Latest Key Developments (Source: Significant Developments)

Fate Therapeutics Prices Public Offering Of 9.26 Mln Common Shares At $13.50/Share
Friday, 21 Sep 2018 

Sept 20 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.26 MILLION COMMON SHARES PRICED AT $13.50PER SHARE.  Full Article

Fate Therapeutics Announces Proposed Public Offering Of Common Stock
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.FATE THERAPEUTICS - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND CLINICAL TRIALS AND NONCLINICAL STUDIES, AMONG OTHERS.  Full Article

Fate Therapeutics Reports Q2 Loss Per Share Of $0.37
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q2 REVENUE $1.0 MILLION VERSUS I/B/E/S VIEW $1.2 MILLION.QTRLY NET LOSS PER COMMON SHARE, BASIC AND DILUTED $0.37.  Full Article

Redmile Group LLC Reports 12.6 Pct Stake In Fate Therapeutics As Of July 31
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Redmile Group LLC: :REDMILE GROUP LLC REPORTS 12.6 PERCENT STAKE IN FATE THERAPEUTICS AS OF JULY 31 - SEC FILING.REDMILE GROUP - ON JULY 31, FATE BOARD APPOINTED REDMILE'S MICHAEL S. LEE TO SERVE AS DIRECTOR UNTIL FATE'S 2021 ANNUAL MEET.REDMILE GROUP - ACQUIRED FATE STOCK FOR INVESTMENT PURPOSE.  Full Article

Fate Therapeutics Announces Pricing Of Public Offering Of Common Stock
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.53 MILLION COMMON SHARES PRICED AT $4.20PER SHARE.  Full Article

BRIEF-Fate Therapeutics Files For Mixed Shelf Of Up To $150 Million

* FATE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text: (https://bit.ly/2KD5gGz) Further company coverage: